	C 2012 Mar 31	C 2013 Mar 31	C 2014 Mar 31	2015 Mar 31	R 2016 Mar 31	2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M PRESS
Total Revenue	1,864	2,145	2,532	3,115	3,776	4,064	3,891	4,946	5,394	6,969	8,960	7,768	7,845	9,360	10,560
Cost of Operating Revenue	940	1,045	1,198	1,576	1,866	1,924	1,977	2,324	2,654	2,998	3,791	4,018	4,124	4,737	4,556
Gross Profit	924	1,100	1,334	1,539	1,911	2,140	1,914	2,622	2,740	3,972	5,169	3,750	3,721	4,623	6,004
Gross Margin	49.6	51.3	52.7	49.4	50.6	52.7	49.2	53.0	50.8	57.0	57.7	48.3	47.4	49.4	56.9
Total Operating Expenses	1,235	1,406	1,607	2,079	2,473	2,701	2,766	3,241	3,754	4,355	5,387	5,742	6,014	6,790	7,582
Operating Profit	629	739	925	1,036	1,304	1,363	1,125	1,706	1,640	2,615	3,572	2,026	1,831	2,570	2,978
Operating Margin	33.8	34.5	36.5	33.3	34.5	33.5	28.9	34.5	30.4	37.5	39.9	26.1	23.3	27.5	28.2
Financing Income/(Expense) - Net	50	42	67	41	91	27	107	120	134	55	109	334	328	345	188
Profit before Taxes	681	781	991	1,072	1,393	1,395	1,231	1,855	1,819	2,666	3,684	2,369	2,163	2,916	3,388
Income Taxes	147	179	218	221	267	335	354	502	443	682	723	545	563	725	820
Profit after Tax	533	602	773	852	1,126	1,060	877	1,353	1,377	1,984	2,960	1,823	1,600	2,191	2,568
PAT Margin	28.6	28.1	30.5	27.3	29.8	26.1	22.5	27.3	25.5	28.5	33.0	23.5	20.4	23.4	24.3
EPS - Basic - ex Extraordinary Items	20.10	22.68	29.13	32.08	21.20	19.97	33.04	50.96	51.85	74.75	111.52	68.69	60.27	82.53	96.75
EPS - Diluted - ex Extraordinary Items	20.10	22.68	29.13	32.08	21.20	19.97	33.04	50.96	51.85	74.75	111.52	68.69	60.27	82.53	96.75
EBIT	629	739	925	1,036	1,304	1,363	1,125	1,706	1,640	2,615	3,572	2,026	1,831	2,570	2,978
EBITDA	691	816	1,017	1,172	1,422	1,486	1,268	1,874	1,826	2,870	3,884	2,369	2,209	2,972	3,441
EBITDA Margin	37.1	38.0	40.2	37.6	37.6	36.6	32.6	37.9	33.9	41.2	43.3	30.5	28.2	31.8	32.6

Balance Sheet

Abridged

Understanding Balance Sheet

Divis Laboratories Ltd. balance sheet covering assets, liabilities, equity and borrowings across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	C 2012 Mar 31	2013 Mar 31	C 2014 Mar 31	R 2015 Mar 31	R 2016 Mar 31	C 2017 Mar 31	R 2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Source:	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	PRESS
Total Current Assets	1,751	1,864	2,256	2,773	3,027	4,011	4,535	4,650	4,680	6,175	8,352	9,312	9,675	10,081	11,096
Long-Term Investments	-	-	-	0	0	0	0	547	0	0	72	77	82	65	136
Property Plant & Equipment - Net	1,274	1,212	1,366	1,523	1,700	2,000	2,109	2,576	3,698	4,410	4,787	4,929	5,513	6,460	8,635
Total Non-Current Assets	1,359	1,275	1,454	1,609	1,875	2,148	2,251	3,388	3,856	4,599	5,023	5,127	5,795	6,851	8,937
Total Assets	2,757	3,139	3,710	4,383	4,902	6,159	6,786	8,038	8,536	10,774	13,375	14,439	15,470	16,932	20,033
Total Current Liabilities	554	554	627	456	520	659	653	847	927	1,112	1,196	1,101	1,278	1,452	2,043
Long Term Debt	3	2	2	1	0	-	-	-	4	4	3	3	2	2	5
Total Non-Current Liabilities	71	84	120	105	89	142	208	234	299	367	451	571	621	511	1,229
Total Liabilities	625	638	747	561	609	801	861	1,081	1,226	1,479	1,647	1,672	1,899	1,963	3,272
Total Shareholders' Equity	2,132	2,501	2,963	3,822	4,293	5,357	5,925	6,957	7,310	9,295	11,728	12,767	13,571	14,969	16,761
Total Equity	2,132	2,501	2,963	3,822	4,293	5,357	5,925	6,957	7,310	9,295	11,728	12,767	13,571	14,969	16,761
Total Liabilities & Equity	2,757	3,139	3,710	4,383	4,902	6,159	6,786	8,038	8,536	10,774	13,375	14,439	15,470	16,932	20,033

Cash Flow

Abridged

Understanding Cash Flow Statement

Divis Laboratories Ltd. cash flow statement covering operating, investing and financing activities across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2012 Mar 31	C 2013 Mar 31	2014 Mar 31	2015 Mar 31	C 2016 Mar 31	R 2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M PRESS
Operating CF bef Changes in Working Cap	614	697	886	992	1,247	1,254	1,072	1,541	1,471	2,267	3,349	2,245	2,166	2,500	2,918
Working Capital - Increase/(Decrease)	-242	-186	-298	-127	-155	-37	-216	-500	-218	-264	-1,370	419	-607	-554	99
Net CF from Operating Activities	372	511	588	865	1,092	1,216	855	1,041	1,253	2,003	1,978	2,664	1,559	1,946	3,017
Capital Expenditures - Net	289	340	246	307	396	377	274	733	1,183	910	713	473	1,003	1,438	2,517
Net CF from Investing Activities	-240	-286	-337	-560	-463	-1,208	-559	-776	-127	18	-2,262	-2,912	-569	-1,099	-2,503
Dividends Paid - Cash - Total	154	201	233	311	639	-	319	320	1,024	-	531	796	796	796	797
Stock - Issuance/(Retirement) - Net	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Debt - LT & ST - Issuance/(Retirement) - Total	34	-22	-15	8	16	5	6	78	-61	-34	-1	0	-1	-1	-2
Net Cash Flow from Financing Activities	-129	-230	-248	-302	-629	5	-313	-242	-1,085	-34	-532	-797	-797	-797	-799
Free Cash Flow to Equity	117	148	327	566	712	844	588	386	9	1,059	1,264	2,191	555	507	498
Free Operating CF net dividend	-71	-30	108	247	57	840	262	-12	-954	1,093	734	1,395	-240	-288	-300
Free Operating CF	83	171	341	558	696	840	581	308	70	1,093	1,265	2,191	556	508	497

Business Segment Analysis

FY End:

Mar 25

Divis Laboratories Ltd. business segment breakdown covering revenue, operating income and assets across key divisions for the selected financial year.

Capex

Manufacture of Active Pharmaceutical Ingredients and Intermediates (100.0%)₹ 1,438.00 Cr

Revenue / Sales

Manufacture of Active Pharmaceutical Ingredients and Intermediates (100.0%)₹ 9,360.00 Cr

Assets

Manufacture of Active Pharmaceutical Ingredients and Intermediates (100.0%)₹ 16,932.00 Cr

Operating Income

Manufacture of Active Pharmaceutical Ingredients and Intermediates (100.0%)₹ 2,570.00 Cr

Regional Segment Analysis

FY End:

Mar 25

Divis Laboratories Ltd. geographic revenue split showing domestic and international market performance across revenue and income for the selected financial year.

Revenue / Sales

Outside India (53.8%)₹ 5,039.00 CrSwitzerland (20.4%)₹ 1,908.00 CrUSA (14.0%)₹ 1,306.00 CrIndia (11.8%)₹ 1,107.00 Cr

Historical Segment Analysis

Track how Divis Laboratories Ltd. segment contributions have evolved over multiple financial years to see which divisions are growing, shrinking or gaining strategic importance.

Capex

Sales

Assets

Operating Income

Business

Regional

Business

	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31

Manufacture of Active Pharmaceutical Ingredients and Intermediates	1,183	910	713	473	1,003	1,438

Frequently Asked Questions

What is the revenue of Divis Laboratories Ltd.?

The latest trailing twelve month revenue of Divis Laboratories Ltd. is ₹ 10,560.00 Cr, reflecting a 1-year growth of 12.82% and a 3-year CAGR of 10.78%. Annual and quarterly revenue trends are available in the Income Statement section.

What is the net profit of Divis Laboratories Ltd.?

The latest trailing twelve month net profit (PAT) of Divis Laboratories Ltd. is ₹ 2,568.00 Cr, with a 3-year earnings CAGR of 12.10%. Detailed profit history across annual and quarterly periods is in the Income Statement section.

What is the EBITDA of Divis Laboratories Ltd.?

The trailing twelve month EBITDA of Divis Laboratories Ltd. is approximately ₹ 2,978.00 Cr (based on an operating margin of 28.20%). EBITDA reflects core operating profitability before interest, taxes, depreciation and amortisation.

What is the EPS of Divis Laboratories Ltd.?

The trailing twelve month Earnings Per Share (EPS) of Divis Laboratories Ltd. is 96.75. EPS trends across annual and quarterly periods are visible in the Income Statement section.

What is the debt level of Divis Laboratories Ltd.?

The debt-to-equity ratio of Divis Laboratories Ltd. stands at 0.00. The interest coverage ratio is 129.48x, reflecting the company's ability to service debt from operating earnings. The full breakdown of total borrowings is in the Balance Sheet section.

What is the book value per share of Divis Laboratories Ltd.?

The estimated book value per share of Divis Laboratories Ltd. is 639.83 (derived from a P/B ratio of 10.58 and market price of ₹ 6,772.00), reflecting the net asset value attributable to each share. See the Balance Sheet section for a full breakdown.

What is the cash flow from operations of Divis Laboratories Ltd.?

The trailing twelve month operating cash flow of Divis Laboratories Ltd. is ₹ 3,017.00 Cr. Annual and quarterly cash flow data is available in the Cash Flow section of the Statements tab.

Does Divis Laboratories Ltd. report consolidated or standalone financials?

Divis Laboratories Ltd. reports consolidated financials. You can toggle between consolidated and standalone views using the switch at the top of each statement section.